Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using a patient’s own T-cells to target tumors. However, they can cause rare but potentially fatal cardiac inflammation ...
The FDA has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
The American Association for the Study of Liver Diseases and Infectious Diseases Society of America have updated guidance on ...
Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...
The study analyzed more than 100 million U.S. medical claims from July 1, 2022, through June 30, 2024, and found that nearly one in three eligible heart failure patients are not being treated with ...
In a clinical practice guideline (CPG) issued by the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense ...
Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...
Background Prehospital delays remain critical barriers to timely acute coronary syndrome (ACS) care, particularly for ...
Background The National Heart Failure Audit gathers data on patients coded at discharge (or death) as having heart failure as ...
Morning Overview on MSN
Doctors surprised by semaglutide’s heart-saving benefits
For years, semaglutide was framed as a powerful tool for diabetes and weight loss. Now cardiologists are confronting a more ...
Clinical trials underrepresent women, children, and adults aged 65 years or older, so diabetes guidelines must be adapted to ...
Al-Gahtani, S. (2026) Review of Literature Investigating the Correlation between Prevalence of Risk Factors Associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback